Juncture Wealth Strategies buys $1,058,124 stake in ABIOMED (ABMD)

ABIOMED (ABMD) : Juncture Wealth Strategies scooped up 2,295 additional shares in ABIOMED during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 10,773 shares of ABIOMED which is valued at $1,058,124.ABIOMED makes up approximately 0.79% of Juncture Wealth Strategies’s portfolio.

ABIOMED opened for trading at $96.86 and hit $98.4 on the upside on Friday, eventually ending the session at $98.22, with a gain of 0.87% or 0.85 points. The heightened volatility saw the trading volume jump to 5,09,032 shares. Company has a market cap of $4,168 M.

Other Hedge Funds, Including , Capstone Asset Management Co reduced its stake in ABMD by selling 560 shares or 4.01% in the most recent quarter. The Hedge Fund company now holds 13,400 shares of ABMD which is valued at $1,316,148. ABIOMED makes up approx 0.04% of Capstone Asset Management Co’s portfolio.Eagle Asset Management Inc boosted its stake in ABMD in the latest quarter, The investment management firm added 179,738 additional shares and now holds a total of 828,523 shares of ABIOMED which is valued at $78,792,537. ABIOMED makes up approx 0.55% of Eagle Asset Management Inc’s portfolio.Creative Planning reduced its stake in ABMD by selling 600 shares or 35.29% in the most recent quarter. The Hedge Fund company now holds 1,100 shares of ABMD which is valued at $104,610. Weaver C. Barksdale Associates added ABMD to its portfolio by purchasing 119 company shares during the most recent quarter which is valued at $11,317. ABIOMED makes up approx 0.01% of Weaver C. Barksdale Associates’s portfolio.

On the company’s financial health, ABIOMED reported $0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Feb 4, 2016. Analyst had a consensus of $0.16. The company had revenue of $85.80 million for the quarter, compared to analysts expectations of $85.81 million. The company’s revenue was up 38.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.30 EPS.

Abiomed Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company’s products include Impella 2.5 a percutaneous micro heart pump with an integrated motor and sensors; Impella CP which is primarily used by either interventional cardiologists to support patients in the catheter lab or by surgeons in the heart surgery suite; Impella 5.0 and Impella LD a percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute; AB5000 a circulatory support system for the temporary support of acute heart failure patients in profound shock and Symphony a minimally invasive implantable cardiac assist device.

Leave a Reply

ABIOMED - Is it time to Sell?

Top Brokerage Firms are advising their investors on ABIOMED. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.